Caravan Biologix — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Caravan Biologix is pioneering an AI-designed, cell-free CAR therapeutic platform using engineered biospheres derived from allogeneic cells. Its core technology, Mini-CAR, is designed to offer superior tumor penetration, reduced toxicity like cytokine release syndrome (CRS), and simplified manufacturing compared to whole-cell therapies. The company's strategy involves building an internal pipeline while actively seeking platform licensing partnerships to develop therapies for oncology and hereditary diseases.

OncologyHereditary DiseaseAutoimmune Disease

Technology Platform

AI-designed CAR-Directed BioSpheres (Mini-CAR): allogeneic, cell-derived nanovesicles engineered with chimeric antigen receptors (CARs) and tunable therapeutic payloads (e.g., apoptotic proteins) designed to emulate immune cell function without using live cells.

Opportunities

The primary opportunity lies in addressing the vast unmet need in solid tumor oncology with an off-the-shelf, safer, and more penetrant therapy compared to current CAR-T cells.

Additionally, the platform's flexibility allows for expansion into lucrative markets for hereditary and autoimmune diseases through both internal programs and high-value licensing partnerships.

Risk Factors

The company faces high technical risk as its novel, unproven cell-free platform must demonstrate efficacy and manufacturability in rigorous preclinical models.

As a pre-revenue private startup, it carries significant financing risk and depends on raising capital to advance its costly R&D.

It also operates in a highly competitive and fast-evolving landscape of cell and gene therapies.

Competitive Landscape

Caravan competes in the advanced cell therapy space, directly challenging established CAR-T leaders (e.g., Novartis, Gilead) and numerous biotechs working on next-gen allogeneic and solid tumor CAR technologies. It also faces emerging competition from other extracellular vesicle and synthetic nanoparticle drug delivery platforms aiming to achieve similar targeted effects.

More companies in Cell & Gene Therapy →More companies in United States →